melanotan aus II (MT-2) Melanotan Peptides Australia

We provide the suitability data to customers for transparency and so they can be confident in the results

PT-141 has been approved by the FDA for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women

Clinical response is usually evaluated after 8 weeks of use

They are not medicines, are not for human or animal consumption, and are supplied with no dosing or medical guidance

Where These Numbers Come From MT-2 has some human clinical data, primarily from sexual dysfunction studies rather than tanning

*Correspondence: Lin Zhang, [email protected] These authors have contributed equally to this work Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers